Phio Pharmaceuticals Corp.
RNA interference in ocular indications
Last updated:
Abstract:
The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules.
Status:
Grant
Type:
Utility
Filling date:
30 Nov 2018
Issue date:
26 May 2020